drugset

drugset / Trial / NCT07123129

A Trial of SHR-7782 for Treatment of Advanced Malignant Tumors

NCT07123129 ↗

Phase 1 Recruiting 200 enrolled Suzhou Suncadia Biopharmaceuticals Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

The main objective of this study is to evaluate the effectiveness and safety of SHR-7782 for participants with advanced malignant cancer.

Timeline

Start: 2025-08-28
Primary completion: 2026-12
Completion: 2027-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	SHR-7782	Unknown	—	—

Indications